Mississauga, ON -- (SBWIRE) -- 05/01/2018 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "40 Million Diabetic Sufferers Could Benefit from Sernova's Cell Pouch Technologies."
Companies mentioned in this article include Sernova Corp. (TSX-Venture:SVA) (OTCQB:SEOVF).
Article Excerpt:
Healthcare costs have spiraled out of control in most countries, especially the U.S., where people can't seem to lead healthy lifestyles. The latest data (from 2016) shows that the adult obesity rates exceeded 35% in five states (led by WV at 37.7%), 30% in 25 states, and 25% in 46 states. Estimates are that obesity costs the U.S. more than $150 billion in healthcare each year. Part of this is due to 1 in 11, or about 30 million Americans, having diabetes, a chronic condition that is often helped by weight loss.
Diabetes is characterized by high levels of blood sugar (also called "blood glucose"). Insulin is a hormone produced in the pancreas by the islets of Langerhans that regulate the amount of glucose in the blood. For people with diabetes, insulin is either not produced (Type 1 diabetes), not enough is produced, or the body doesn't use it right (Type 2 diabetes). People with Type 1 diabetes are insulin-dependent, meaning they must use a device (albeit a syringe or some type of automatic device) to inject insulin into their body to survive. Type 2 diabetic subjects can be either insulin-free or insulin-dependent, based upon their stage of disease.
Type 2 is the most common type of diabetes, accounting for about 95% of all cases. It is estimated that there are more than 40 million people with diabetes – both Type 1 and Type 2 – worldwide.
At the leading edge of new devices and therapeutic cells for treatment of diabetes is a small powerhouse, London, Ontario-based Sernova Corp. (TSX-Venture:SVA) (OTCQB:SEOVF), the creator of the revolutionary Cell Pouch System™. The Cell Pouch is a novel implantable and scalable medical device that forms a favorable environment within its chambers for the housing and long-term survival and function of therapeutic cells. The cells could be integral to any number of functions, including releasing necessary proteins or hormones missing from the body to treat chronic diseases, such as diabetes, as an alternative to daily administration of drugs.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_ca/special-reports/896/40-million-diabetic-sufferers-could-benefit-from-sernovas-cell-pouch-technologies.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has been compensated three thousand dollars from a third-party, Frontier Consulting, Ltd. for its efforts in presenting the SVA profile on its web site and distributing it to its database of subscribers as well as other services. For a complete disclaimer, investors are encouraged to click here: http://www.allpennystocks.com/spotlight/30/sernova-corp-tsx-venturesvaotcqbseovf.htm.